Oladapo Yeku, MD, PhD, FACP, instructor of Medicine, Harvard Medical School, clinical assistant of Medicine, Massachusetts General Hospital, discusses the evaluation of COM701 with nivolumab (Opdivo) in patients with platinum-resistant epithelial ovarian cancer.

Data from a phase 1 trial (NCT03667716) evaluating the safety, tolerability, and preliminary clinical activity of COM701 plus nivolumab were presented at the 2022 ESMO Immuno-Oncology Annual Congress.

Among 20 evaluable patients, the combination elicited an overall response rate of 10% and a disease control rate of 45%, Yeku says. Moreover, the majority of adverse effects reported were grade 1/2 and tolerable, including fatigue and nausea, Yeku adds.

These results align with the hypothesis that there are still combinations to evaluate in the platinum-resistant setting, Yeku continues. The efficacy signals observed on the trial and translational research, including increased T-cell infiltration, investigators can continue to build on combinations, Yeku explains.

With a signal of potential benefit and data on toxicities, future clinical trials can explore ways to maximize the proportion of patients who benefit from these treatments, Yeku concludes.

Videos

Oladapo Yeku, MD, PhD, FACP, discusses the evaluation of COM701 with nivolumab in patients with platinum-resistant epithelial ovarian cancer.


Oladapo Yeku, MD, PhD, FACP

Articles

Dr. Yeku on the Evaluation of COM701 Plus Nivolumab in Platinum-Resistant Ovarian Cancer